IL239491A0 - Dystrophin Antisense Oligonucleotides Exon Skipping Factors, Vectors and Preparations Containing Them and Their Uses - Google Patents
Dystrophin Antisense Oligonucleotides Exon Skipping Factors, Vectors and Preparations Containing Them and Their UsesInfo
- Publication number
- IL239491A0 IL239491A0 IL239491A IL23949115A IL239491A0 IL 239491 A0 IL239491 A0 IL 239491A0 IL 239491 A IL239491 A IL 239491A IL 23949115 A IL23949115 A IL 23949115A IL 239491 A0 IL239491 A0 IL 239491A0
- Authority
- IL
- Israel
- Prior art keywords
- dystrophin
- vectors
- compositions
- same
- antisense oligonucleotides
- Prior art date
Links
- 108020000948 Antisense Oligonucleotides Proteins 0.000 title 1
- 102000001039 Dystrophin Human genes 0.000 title 1
- 108010069091 Dystrophin Proteins 0.000 title 1
- 239000000074 antisense oligonucleotide Substances 0.000 title 1
- 238000012230 antisense oligonucleotides Methods 0.000 title 1
- 230000001939 inductive effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000013598 vector Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/314—Phosphoramidates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
- C12N2310/3181—Peptide nucleic acid, PNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3233—Morpholino-type ring
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3513—Protein; Peptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/33—Alteration of splicing
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261739968P | 2012-12-20 | 2012-12-20 | |
| PCT/US2013/077216 WO2014100714A1 (en) | 2012-12-20 | 2013-12-20 | Improved exon skipping compositions for treating muscular dystrophy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL239491A0 true IL239491A0 (en) | 2015-08-31 |
Family
ID=49950080
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL239491A IL239491A0 (en) | 2012-12-20 | 2015-06-18 | Dystrophin Antisense Oligonucleotides Exon Skipping Factors, Vectors and Preparations Containing Them and Their Uses |
Country Status (13)
| Country | Link |
|---|---|
| US (5) | US20150361428A1 (enExample) |
| EP (2) | EP3885439A1 (enExample) |
| JP (3) | JP2016502858A (enExample) |
| KR (2) | KR20150099804A (enExample) |
| CN (2) | CN111440796A (enExample) |
| AU (3) | AU2013364158A1 (enExample) |
| BR (1) | BR112015014987A2 (enExample) |
| CA (1) | CA2894899A1 (enExample) |
| EA (1) | EA201591178A1 (enExample) |
| HK (1) | HK1216902A1 (enExample) |
| IL (1) | IL239491A0 (enExample) |
| MX (2) | MX2015008035A (enExample) |
| WO (1) | WO2014100714A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3808845A1 (en) | 2004-06-28 | 2021-04-21 | The University Of Western Australia | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
| ES2852549T3 (es) | 2005-02-09 | 2021-09-13 | Sarepta Therapeutics Inc | Composición antisentido para tratamiento de la atrofia muscular |
| CA3066050A1 (en) | 2008-10-24 | 2010-04-29 | Sarepta Therapeutics, Inc. | Multiple exon skipping compositions for dmd |
| SI2499249T1 (sl) | 2009-11-12 | 2019-02-28 | The University Of Western Australia, | Protismiselne molekule in postopki zdravljenja patologij |
| TWI541024B (zh) | 2010-09-01 | 2016-07-11 | 日本新藥股份有限公司 | 反義核酸 |
| US20130085139A1 (en) | 2011-10-04 | 2013-04-04 | Royal Holloway And Bedford New College | Oligomers |
| IL280443B (en) | 2013-03-14 | 2022-07-01 | Sarepta Therapeutics Inc | Preparations that skip axon for the treatment of muscular dystrophy |
| EP3760720A1 (en) * | 2013-03-14 | 2021-01-06 | Sarepta Therapeutics, Inc. | Exon skipping compositions for treating muscular dystrophy |
| MX373959B (es) | 2013-03-15 | 2020-07-13 | Sarepta Therapeutics Inc | Composición para usarse en el tratamiento de la distrofia muscular de duchenne (dmd). |
| MA41795A (fr) | 2015-03-18 | 2018-01-23 | Sarepta Therapeutics Inc | Exclusion d'un exon induite par des composés antisens dans la myostatine |
| CA2981960C (en) | 2015-04-08 | 2023-09-19 | The University Of Chicago | Compositions and methods for correcting limb girdle muscular dystrophy type 2c using exon skipping |
| MA45819A (fr) | 2015-10-09 | 2018-08-15 | Sarepta Therapeutics Inc | Compositions et méthodes pour traiter la dystrophie musculaire de duchenne et troubles associés |
| FR3044926B1 (fr) * | 2015-12-09 | 2020-01-31 | Genethon | Outils de therapie genique efficaces pour le saut de l'exon 53 de la dystrophine |
| JOP20200228A1 (ar) | 2015-12-21 | 2017-06-16 | Novartis Ag | تركيبات وطرق لخفض تعبير البروتين tau |
| WO2017136435A1 (en) | 2016-02-01 | 2017-08-10 | The Usa, As Represented By The Secretary, Department Of Health And Human Services Office Of Technology Transfer National Institute Of Health | Compounds for modulating fc-epsilon-ri-beta expression and uses thereof |
| MA45328A (fr) | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | Compositions acide nucléique-polypeptide et utilisations de celles-ci |
| CN109311919A (zh) | 2016-06-30 | 2019-02-05 | 萨勒普塔医疗公司 | 用于肌肉萎缩症的外显子跳跃寡聚体 |
| WO2018009547A1 (en) | 2016-07-05 | 2018-01-11 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Diagnosing col6-related disorders and methods for treating same |
| WO2018052549A1 (en) | 2016-09-19 | 2018-03-22 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Zika virus vaccines |
| MD3554553T2 (ro) | 2016-12-19 | 2022-10-31 | Sarepta Therapeutics Inc | Conjugați de oligomeri de omitere a exonului, pentru distrofie musculară |
| MA65895B1 (fr) | 2016-12-19 | 2024-06-28 | Sarepta Therapeutics, Inc. | Conjugués d'oligomères induisant le saut d'exons pour la dystrophie musculaire |
| DK3554552T3 (da) | 2016-12-19 | 2022-10-24 | Sarepta Therapeutics Inc | Exon-skipping-oligomerkonjugater mod muskeldystrofi |
| WO2018129384A1 (en) | 2017-01-06 | 2018-07-12 | Avidity Biosciences Llc | Nucleic acid-polypeptide compositions and methods of inducing exon skipping |
| WO2018152526A1 (en) | 2017-02-20 | 2018-08-23 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Zika virus vaccines |
| GB201711809D0 (en) | 2017-07-21 | 2017-09-06 | Governors Of The Univ Of Alberta | Antisense oligonucleotide |
| EA201991450A1 (ru) * | 2017-09-22 | 2019-12-30 | Сарепта Терапьютикс, Инк. | Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии |
| JP2021521794A (ja) * | 2018-04-26 | 2021-08-30 | サレプタ セラピューティクス， インコーポレイテッド | 筋ジストロフィーに対するエクソンスキッピングオリゴマーおよびオリゴマーコンジュゲート |
| US10758629B2 (en) | 2018-05-29 | 2020-09-01 | Sarepta Therapeutics, Inc. | Exon skipping oligomer conjugates for muscular dystrophy |
| JP7658900B2 (ja) * | 2018-12-13 | 2025-04-08 | サレプタ セラピューティクス， インコーポレイテッド | 筋ジストロフィーに対するエクソンスキッピングオリゴマーコンジュゲート |
| CN118516348B (zh) * | 2024-07-23 | 2025-01-17 | 深川生物科技(山东)股份公司 | 单链核酸或双链核酸及在制备治疗杜氏肌营养不良的药物中的应用 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH445129A (fr) | 1964-04-29 | 1967-10-15 | Nestle Sa | Procédé pour la préparation de composés d'inclusion à poids moléculaire élevé |
| US3459731A (en) | 1966-12-16 | 1969-08-05 | Corn Products Co | Cyclodextrin polyethers and their production |
| US3453257A (en) | 1967-02-13 | 1969-07-01 | Corn Products Co | Cyclodextrin with cationic properties |
| US3426011A (en) | 1967-02-13 | 1969-02-04 | Corn Products Co | Cyclodextrins with anionic properties |
| US3453259A (en) | 1967-03-22 | 1969-07-01 | Corn Products Co | Cyclodextrin polyol ethers and their oxidation products |
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| US5185444A (en) | 1985-03-15 | 1993-02-09 | Anti-Gene Deveopment Group | Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages |
| US5506337A (en) | 1985-03-15 | 1996-04-09 | Antivirals Inc. | Morpholino-subunit combinatorial library and method |
| US5521063A (en) | 1985-03-15 | 1996-05-28 | Antivirals Inc. | Polynucleotide reagent containing chiral subunits and methods of use |
| US5166315A (en) | 1989-12-20 | 1992-11-24 | Anti-Gene Development Group | Sequence-specific binding polymers for duplex nucleic acids |
| US5217866A (en) | 1985-03-15 | 1993-06-08 | Anti-Gene Development Group | Polynucleotide assay reagent and method |
| JP3022967B2 (ja) | 1985-03-15 | 2000-03-21 | アンチバイラルズ インコーポレイテッド | 立体規則性ポリヌクレオチド結合ポリマー |
| US4737323A (en) | 1986-02-13 | 1988-04-12 | Liposome Technology, Inc. | Liposome extrusion method |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5149797A (en) | 1990-02-15 | 1992-09-22 | The Worcester Foundation For Experimental Biology | Method of site-specific alteration of rna and production of encoded polypeptides |
| WO1994002595A1 (en) | 1992-07-17 | 1994-02-03 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for treatment of animal diseases |
| DE69435005T2 (de) | 1993-05-11 | 2008-04-17 | The University Of North Carolina At Chapel Hill | Antisense Oligonukleotide die anomales Splicing verhindern und deren Verwendung |
| US5885613A (en) | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
| US5753613A (en) | 1994-09-30 | 1998-05-19 | Inex Pharmaceuticals Corporation | Compositions for the introduction of polyanionic materials into cells |
| US5820873A (en) | 1994-09-30 | 1998-10-13 | The University Of British Columbia | Polyethylene glycol modified ceramide lipids and liposome uses thereof |
| IL115849A0 (en) | 1994-11-03 | 1996-01-31 | Merz & Co Gmbh & Co | Tangential filtration preparation of liposomal drugs and liposome product thereof |
| WO1999042091A2 (en) | 1998-02-19 | 1999-08-26 | Massachusetts Institute Of Technology | Use of polycations as endosomolytic agents |
| US6683173B2 (en) | 1998-04-03 | 2004-01-27 | Epoch Biosciences, Inc. | Tm leveling methods |
| US6210892B1 (en) | 1998-10-07 | 2001-04-03 | Isis Pharmaceuticals, Inc. | Alteration of cellular behavior by antisense modulation of mRNA processing |
| US7070807B2 (en) | 1999-12-29 | 2006-07-04 | Mixson A James | Branched histidine copolymers and methods for using same |
| CA2394758A1 (en) | 1999-12-29 | 2001-07-05 | A. James Mixson | Histidine-containing copolymers enhance pharmaceutical agent delivery |
| DE60231975D1 (de) | 2001-05-24 | 2009-05-28 | Genzyme Corp | Muskelspezifische expressionsvektoren |
| EP3808845A1 (en) | 2004-06-28 | 2021-04-21 | The University Of Western Australia | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
| CA2629323A1 (en) | 2005-11-10 | 2007-05-24 | The University Of North Carolina At Chapel Hill | Splice switching oligomers for tnf superfamily receptors and their use in treatment of disease |
| PL2735568T3 (pl) | 2006-05-10 | 2018-02-28 | Sarepta Therapeutics, Inc. | Analogi oligonukleotydowe mające kationowe połączenia pomiędzy podjednostkami |
| US20100016215A1 (en) | 2007-06-29 | 2010-01-21 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
| US8076476B2 (en) | 2007-11-15 | 2011-12-13 | Avi Biopharma, Inc. | Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits |
| US8299206B2 (en) | 2007-11-15 | 2012-10-30 | Avi Biopharma, Inc. | Method of synthesis of morpholino oligomers |
| WO2009127230A1 (en) | 2008-04-16 | 2009-10-22 | Curevac Gmbh | MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION |
| US8084601B2 (en) * | 2008-09-11 | 2011-12-27 | Royal Holloway And Bedford New College Royal Holloway, University Of London | Oligomers |
| CA3066050A1 (en) * | 2008-10-24 | 2010-04-29 | Sarepta Therapeutics, Inc. | Multiple exon skipping compositions for dmd |
| SI2499249T1 (sl) | 2009-11-12 | 2019-02-28 | The University Of Western Australia, | Protismiselne molekule in postopki zdravljenja patologij |
| KR102095478B1 (ko) | 2010-05-28 | 2020-04-01 | 사렙타 쎄러퓨틱스, 인코퍼레이티드 | 변형된 서브유니트간 결합 및/또는 말단 그룹을 갖는 올리고뉴클레오타이드 유사체 |
| TWI541024B (zh) * | 2010-09-01 | 2016-07-11 | 日本新藥股份有限公司 | 反義核酸 |
| KR102339196B1 (ko) | 2011-05-05 | 2021-12-15 | 사렙타 쎄러퓨틱스, 인코퍼레이티드 | 펩타이드 올리고뉴클레오타이드 접합체 |
-
2013
- 2013-12-20 EP EP21152285.9A patent/EP3885439A1/en not_active Withdrawn
- 2013-12-20 KR KR1020157019523A patent/KR20150099804A/ko not_active Ceased
- 2013-12-20 CN CN202010276936.2A patent/CN111440796A/zh active Pending
- 2013-12-20 BR BR112015014987A patent/BR112015014987A2/pt not_active Application Discontinuation
- 2013-12-20 CN CN201380073536.XA patent/CN106414739A/zh active Pending
- 2013-12-20 EA EA201591178A patent/EA201591178A1/ru unknown
- 2013-12-20 WO PCT/US2013/077216 patent/WO2014100714A1/en not_active Ceased
- 2013-12-20 MX MX2015008035A patent/MX2015008035A/es unknown
- 2013-12-20 EP EP13819166.3A patent/EP2935584A1/en not_active Withdrawn
- 2013-12-20 KR KR1020207033842A patent/KR20200143739A/ko not_active Ceased
- 2013-12-20 AU AU2013364158A patent/AU2013364158A1/en not_active Abandoned
- 2013-12-20 CA CA2894899A patent/CA2894899A1/en not_active Abandoned
- 2013-12-20 JP JP2015549818A patent/JP2016502858A/ja not_active Withdrawn
- 2013-12-20 HK HK16104638.2A patent/HK1216902A1/zh unknown
-
2015
- 2015-06-18 US US14/743,856 patent/US20150361428A1/en not_active Abandoned
- 2015-06-18 IL IL239491A patent/IL239491A0/en unknown
- 2015-06-19 MX MX2019008164A patent/MX2019008164A/es unknown
-
2017
- 2017-01-31 US US15/420,823 patent/US20170369875A1/en not_active Abandoned
-
2018
- 2018-04-20 JP JP2018081272A patent/JP2018110601A/ja active Pending
-
2019
- 2019-01-11 JP JP2019003308A patent/JP2019050834A/ja active Pending
- 2019-10-21 AU AU2019253778A patent/AU2019253778A1/en not_active Abandoned
- 2019-12-04 US US16/703,110 patent/US20200339985A1/en not_active Abandoned
-
2021
- 2021-10-11 US US17/498,115 patent/US20220259592A1/en not_active Abandoned
-
2022
- 2022-03-09 AU AU2022201628A patent/AU2022201628A1/en not_active Abandoned
- 2022-05-11 US US17/741,758 patent/US20230104708A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MX2019008164A (es) | 2019-09-13 |
| AU2019253778A1 (en) | 2019-11-07 |
| JP2019050834A (ja) | 2019-04-04 |
| AU2013364158A1 (en) | 2015-07-09 |
| CN106414739A (zh) | 2017-02-15 |
| KR20150099804A (ko) | 2015-09-01 |
| EP2935584A1 (en) | 2015-10-28 |
| US20230104708A1 (en) | 2023-04-06 |
| EA201591178A1 (ru) | 2015-11-30 |
| BR112015014987A2 (pt) | 2017-08-15 |
| US20220259592A1 (en) | 2022-08-18 |
| EP3885439A1 (en) | 2021-09-29 |
| US20150361428A1 (en) | 2015-12-17 |
| US20170369875A1 (en) | 2017-12-28 |
| WO2014100714A1 (en) | 2014-06-26 |
| CN111440796A (zh) | 2020-07-24 |
| HK1216902A1 (zh) | 2016-12-09 |
| US20200339985A1 (en) | 2020-10-29 |
| AU2022201628A1 (en) | 2022-03-31 |
| JP2016502858A (ja) | 2016-02-01 |
| JP2018110601A (ja) | 2018-07-19 |
| MX2015008035A (es) | 2016-03-17 |
| CA2894899A1 (en) | 2014-06-26 |
| KR20200143739A (ko) | 2020-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL239491A0 (en) | Dystrophin Antisense Oligonucleotides Exon Skipping Factors, Vectors and Preparations Containing Them and Their Uses | |
| IL238250A0 (en) | Selective antisense compounds and their use | |
| DK2922554T3 (en) | Terminalt modificeret rna | |
| IL237066B (en) | Glycoconjugation processes and preparations | |
| SG10201707706TA (en) | High-transduction-efficiency raav vectors, compositions, and methods of use | |
| ZA201501709B (en) | Cosmetic biphotonic compositions | |
| SI2612917T1 (sl) | Protismiselna nukleinska kislina | |
| ZA201502942B (en) | Laundry compositions | |
| SG11201406395VA (en) | Cosmetic composition carrier comprising foams | |
| AP2014008084A0 (en) | Compositions comprising shortacting benzodiazepines | |
| GB201220354D0 (en) | Dermal compositions | |
| SG11201405008SA (en) | Fabric softener compositions | |
| ZA201502548B (en) | Laundry compositions | |
| IL233824A (en) | Compounds 1h - Indazole - 3 - Carboxamide, preparations containing them and their use | |
| EP2868312A4 (en) | CAPILLARY DYE COMPOSITION | |
| EP2919751A4 (en) | COSMETIC COMPOSITIONS WITH SEAFOOD | |
| IL237542B (en) | Amphiphilic compounds, their preparations and uses | |
| EP2874641A4 (en) | COMPOSITIONS INCREASING THE GLUTATHION RATE AND USES THEREOF | |
| EP2928903A4 (en) | OLIGONUKLEOTIDREZEPTUR | |
| EP2867199A4 (en) | STABLE COMPOSITIONS OF ESOTRERODINE | |
| GB201300064D0 (en) | Microparticle compositions | |
| IL267888B (en) | Amphiphilic compounds, their preparations and uses | |
| IL237540B (en) | Amphiphilic compounds, their preparations and uses | |
| IL233475A (en) | Carbocyclic nucleosides, preparations containing them and their uses | |
| IL243174B (en) | Antisense oligonucleotide preparations |